Findings seen among older patients with incident atrial fibrillation receiving warfarin or apixaban
Your search for Warfarin returned 119 results
Noninferiority not found compared with standard-intensity prophylaxis with hip or knee arthroplasty
Findings seen in warfarin-treated patients with history of international normalized ratio instability
Updated guidelines also emphasize weight loss for overweight, obese patients with atrial fibrillation
For patients initiating oral anticoagulant therapy, the incidence of hospitalization for upper gastrointestinal bleeding is highest and lowest with rivaroxaban and apixaban, respectively.
While the use of NSAIDs was low in the ARISTOTLE trial, NSAID users had a higher risk for bleeding than non-users.
The researchers found that VTE events occurred in 1.38% of patients, including 4.79% of those who received no pharmacologic prophylaxis, 1.16% treated with aspirin alone, 1.42% of those treated with anticoagulation alone, and 1.31% prescribed both aspirin and anticoagulation.
Compared with warfarin, apixaban was correlated with reduced risk of major bleeding and intracranial bleeding (adjusted hazard ratios, 0.66 and 0.4, respectively) and dabigatran was correlated with reduced risk of intracranial bleeding (adjusted hazard ratio, 0.45) among patients with atrial fibrillation.
Similar number of out-of-range next INR values for patients with, without extended testing interval
The researchers found that the risk of developing an intraocular hemorrhage was reduced with dabigatran or rivaroxaban at 365 days (hazard ratio, 0.75; 95% confidence interval, 0.58 to 0.97; P=0.03) but not at 90 days (hazard ratio, 0.73; 95% confidence interval, 0.22 to 2.63; P=0.13).